Sandoz launches generic paclitaxel in single-dose vial

Sandoz is offering a generic paclitaxel formulation, which is the first FDA-approved ANDA to BioScience’s Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension, albumin-bound). 

Sandoz paclitaxel protein-bound particles for injectable suspension (albumin-bound) is indicated for the treatment of patients with metastatic breast cancer. The launch of the lyophilized powder for injection containing 100 mg of paclitaxel in a single-dose vial for intravenous use follows approval by the FDA on Oct. 8, 2024.

Keren Haruvi, president of Sandoz North America, said, “An estimated 168,000 women in the U.S. are living with metastatic breast cancer. While rare, men can also develop metastatic breast cancer. This milestone is another proof point of our commitment to provide access to life-changing medicines for all who need them.” 

[Read more: Novartis completes Spin-off of Sandoz generics, biosimilars business]

Sandoz paclitaxel protein-bound particles for injectable suspension (albumin-bound) was developed in partnership with Jiangsu Hengrui Pharmaceuticals. 

[Read more: Prioritizing Lower-Priced Biosimilar Medications]